Biocytogen Reaches Clinical Milestone as First Patient Dosed in IDEAYA's B7H3/PTK7 Bispecific ADC Phase 1 Trial
核心洞察
Biocytogen (搜索) announces a significant clinical milestone with the first patient dosed in a Phase 1 trial of IDEAYA (搜索)'s first-in-class B7H3 (搜索)/PTK7 (搜索) bispecific TOP1 (搜索) ADC IDE034.
The company has established approximately 280 therapeutic antibody and clinical asset agreements globally, including partnerships with multinational pharmaceutical companies.
Biocytogen (搜索)'s proprietary RenMice platforms enable fully human antibody discovery and have generated an off-the-shelf library of over 1,000,000 antibody sequences against more than 1,000 targets.
Biocytogen (搜索) has achieved a significant clinical milestone with the first patient dosed in a Phase 1 trial of IDEAYA (搜索)'s first-in-class B7H3 (搜索)/PTK7 (搜索) bispecific TOP1 (搜索) antibody-drug conjugate (ADC) IDE034. This development marks an important advancement in the field of bispecific ADC therapeutics, representing a novel approach to targeted cancer (搜索) treatment.
Novel Bispecific ADC Technology
The IDE034 compound represents a first-in-class bispecific TOP1 (搜索) ADC that targets both B7H3 (搜索) and PTK7 (搜索), two important cancer (搜索)-associated antigens. This dual-targeting approach potentially offers enhanced specificity and efficacy compared to traditional single-target therapies. The TOP1 payload mechanism adds another layer of therapeutic potential by targeting topoisomerase I, a critical enzyme involved in DNA replication.
Biocytogen's Platform Capabilities
Biocytogen (搜索) has independently developed its proprietary RenMice platforms, including RenMab, RenLite, RenNano, RenTCR, and RenTCR mimic technologies. These platforms enable fully human monoclonal, bispecific, and multispecific antibody discovery, as well as bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery.
The company has established RenSuper Biologics as a sub-brand to explore global partnerships, offering an off-the-shelf library of more than 1,000,000 fully human antibody sequences against over 1,000 targets for worldwide collaboration.
Global Partnership Network
As of June 30, 2025, Biocytogen (搜索) has established approximately 280 therapeutic antibody and multiple clinical asset co-development, out-licensing, and transfer agreements around the globe. The company has also secured over 50 target-nominated RenMice licensing projects, including several partnerships with multinational pharmaceutical companies.
Preclinical Research Infrastructure
Beyond antibody discovery, Biocytogen (搜索) pioneered the generation of drug target knock-in humanized models for preclinical research. The company currently provides several thousand off-the-shelf animal and cell models under its BioMice sub-brand, along with preclinical pharmacology and gene-editing services for clients worldwide.
Global Operations
Headquartered in Beijing, Biocytogen (搜索) maintains a global presence with branches in multiple locations across China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco, San Diego), and Germany (Heidelberg). This international footprint supports the company's collaborative approach to drug development and its partnerships with pharmaceutical companies worldwide.